Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Feda H. Hamdan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2455-2435; OpenAlex author ID A5055388147. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 10

  1. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  2. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  3. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  4. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  5. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-20-2874↗
  6. Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer. Last author DOI 10.3390/cells10050966↗
  7. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  8. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  9. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network. Co-author DOI 10.1073/pnas.1812915116↗
  10. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer Co-author DOI 10.3390/epigenomes2020008↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steven A. Johnsen · 10 shared papers, 2018–2024 · strength 1.34
  2. Elisabeth Heßmann · 6 shared papers, 2019–2024 · strength 0.68
  3. Ana P. Kutschat · 4 shared papers, 2021–2023 · strength 0.61
  4. Stephan A. Hahn · 4 shared papers, 2020–2024 · strength 0.49
  5. Jochen Gaedcke · 4 shared papers, 2019–2023 · strength 0.46
  6. Jens Thomas Siveke · 4 shared papers, 2020–2023 · strength 0.45
  7. Volker Ellenrieder · 4 shared papers, 2019–2024 · strength 0.42
  8. Xin Wang · 3 shared papers, 2021–2023 · strength 0.38
  9. Zeynab Najafova · 3 shared papers, 2021–2023 · strength 0.38
  10. Amro M. Abdelrahman · 2 shared papers, 2023 · strength 0.27
  11. Jennifer A. Yonkus · 2 shared papers, 2023 · strength 0.27
  12. Joana E. Aggrey-Fynn · 2 shared papers, 2023 · strength 0.27
  13. Rondell Patrell Graham · 2 shared papers, 2023 · strength 0.27
  14. Roberto Alva‐Ruiz · 2 shared papers, 2023 · strength 0.27
  15. Mark Joseph Truty · 2 shared papers, 2023 · strength 0.27
  16. Shiv K. Singh · 2 shared papers, 2021–2024 · strength 0.22
  17. Maximilian Reichert · 2 shared papers, 2021–2024 · strength 0.22
  18. Günter Schneider · 2 shared papers, 2021–2024 · strength 0.22
  19. Albrecht Neeße · 2 shared papers, 2019–2024 · strength 0.21
  20. Patrick Christian Hermann · 1 shared paper, 2023 · strength 0.14
  21. Maria Ulisse · 1 shared paper, 2024 · strength 0.13
  22. Marie C. Hasselluhn · 1 shared paper, 2024 · strength 0.13
  23. Ulrich Sax · 1 shared paper, 2024 · strength 0.13
  24. Lennart Versemann · 1 shared paper, 2024 · strength 0.13
  25. Carolin Schneider · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.